Search

This study was conducted to evaluate the safety profile of Pantohematogen, a substance derived from the velvet antlers of the Altai Wapiti, which is commonly used as a functional ingredient in dietary supplements. In this clinical research, both male and female Wistar rats received the maximum tolerable intragastric dose of Pantohematogen. Over the course of six months, researchers monitored the animals for changes in general health status, body mass, hematologic and bone marrow parameters, and the functioning of major organs, including the liver, kidneys, heart, and brain.Throughout the experimental period, the animals exhibited stable behavior and maintained normal fur condition, appetite, reflex responses, and gastrointestinal and urinary tract function. No signs of a toxic response were detected following intragastric administration. However, administration of Pantohematogen at 250 and 500 mg/kg resulted in increased liver mass and reduced testicular size in male rats. This condition persisted for 2 weeks after treatment cessation. Other internal organs showed no abnormalities when compared with control and untreated animals.Importantly, the tested doses exceeded standard human-equivalent levels (per kilogram of body weight) by factors of 2, 10, and 20, respectively. Despite this, the findings indicated no evident toxicological impact from Pantohematogen exposure. This research was conducted at the Tomsk National Research Medical Center of the Russian Academy of Sciences under the supervision of Dr. N.I. Suslov, Doctor of Medical Science.

Artificial intelligence is rapidly entering pharmaceutical manufacturing through predictive analytics, process analytical technology, continuous manufacturing platforms, and data-driven quality control. These developments promise earlier detection of process deviation, adaptive optimization of critical process parameters, and more responsive assurance of critical quality attributes. Yet the dominant regulatory and quality vocabulary remains anchored in Quality-by-Design, a paradigm built around pre-defined knowledge, structured risk assessment, and validated control strategies. The central problem is that AI-assisted manufacturing systems do not behave like conventional pharmaceutical processes governed solely through fixed design spaces. Machine learning models may change performance as data distributions shift, as sensors age, as materials vary, or as feedback loops alter the operating environment. This creates a governance gap between the static logic of pre-validation and the dynamic reality of algorithmic decision-making. This critical conceptual review examines whether Quality-by-Design remains sufficient for AI-assisted pharmaceutical manufacturing. It argues that QbD is still necessary but no longer sufficient because it was designed for processes whose boundaries, models, and control logic can be defined before routine operation. AI-assisted systems require an additional governance logic capable of supervising data, models, explanations, adaptation, and accountability throughout the product lifecycle. The review develops the concept of Quality-by-Intelligence as a forward-looking governance framework. QbI does not discard QbD; rather, it extends it by embedding data stewardship, model lifecycle management, explainable decision-making, adaptive risk control, and regulatory translation into the pharmaceutical quality system. Its purpose is to govern not only the manufacturing process, but also the intelligence layer that increasingly mediates quality decisions. Quality-by-Intelligence reframes pharmaceutical quality as an adaptive, evidence-generating, and accountable system rather than a one-time design achievement. The transition will require new regulatory expectations, new validation evidence, new operator competencies, and stronger collaboration between industry, regulators, and academic experts. Without this shift, AI may be deployed into manufacturing faster than the quality systems needed to govern it.

Nanomedicines promise therapeutic advantages that are difficult to achieve with conventional dosage forms, including improved targeting, altered pharmacokinetics, protected delivery of fragile payloads, and platform adaptability across drug classes. Yet these benefits depend on manufacturing systems that can repeatedly generate nanoscale products within narrow physicochemical and biological performance windows. The central difficulty is that small changes in process conditions can produce disproportionate changes in particle size, morphology, surface properties, encapsulation efficiency, release behaviour, and biological interaction. Despite decades of academic activity, the translation of nanomedicine from laboratory prototypes to routine clinical and industrial products remains limited. Many formulations are optimised in small batches under conditions that are poorly suited to pilot or commercial production. As a result, promising nanocarriers may fail not because their therapeutic concept is weak, but because their quality attributes cannot be reproduced reliably at scale. The analysis identifies a systemic mismatch between laboratory-optimised formulation methods and industrial requirements for control, documentation, comparability, continuous monitoring, and GMP-ready reproducibility. Four tables synthesise manufacturing platforms, scale-up fragility points, reproducibility challenges, and regulatory or industrial barriers. Together, these syntheses support a translational quality framework centred on process understanding, platform logic, critical quality attributes, and regulatory co-evolution. The review concludes that nanomedicine translation cannot rely on linear scale-up assumptions. Robust translation requires a shift toward platform-based manufacturing, quality-by-design development, integrated process analytical technology, orthogonal characterisation, predictive scale-down models, and shared regulatory learning. Nanomedicines will become clinically credible only when therapeutic innovation is matched by reproducible, affordable, and auditable manufacturing systems.

Continuous pharmaceutical manufacturing has matured from a technical alternative to batch production into a strategically important manufacturing paradigm. Its promise lies in integrated material flow, smaller production footprints, improved process understanding, flexible scale-out, and the possibility of real-time quality assurance. Yet the quality systems used to govern continuous manufacturing often remain conceptually anchored in batch-era assumptions. The central problem addressed in this article is the mismatch between continuous manufacturing’s dynamic data environment and the inherited quality logic of discrete batch testing, fixed specifications, and retrospective release decisions. In batch quality logic, quality is often treated as a property confirmed after production. In continuous manufacturing, however, quality must be interpreted, predicted, and controlled while the process is still unfolding. This article proposes Lifecycle Intelligence as a theory-driven model for rethinking quality in continuous pharmaceutical manufacturing systems. Lifecycle Intelligence is defined as a quality paradigm in which process data, predictive models, control strategies, and lifecycle learning mechanisms are integrated to maintain quality dynamically across development, validation, commercial production, and post-approval improvement. The model shifts attention from isolated product release to continuous quality cognition. The argument advanced is that continuous manufacturing cannot reach its full quality and regulatory potential if it is governed primarily by batch quality logic. A lifecycle intelligence paradigm is needed to convert continuous data streams into validated quality decisions. This shift will require not only technical advances, but also new validation practices, model governance structures, regulatory dialogue, and workforce capabilities.

The pharmaceutical industry is entering a period of accelerated digital transformation, driven by real-time sensing, automation, digital twins, advanced analytics, and connected healthcare technologies. Yet this transformation remains uneven across the pharmaceutical value chain. Manufacturing systems, quality systems, distribution infrastructures, and patient-facing technologies often evolve as separate digital domains rather than as components of one connected cyber-physical enterprise. This fragmentation limits the capacity of pharmaceutical organizations to use data as a continuous operational resource. A manufacturing line may generate rich process data, a quality system may generate release decisions, a distribution network may generate environmental and traceability records, and a connected device may generate adherence or use data, but these signals are rarely integrated into a unified architecture. As a result, the industry remains only partially able to close the loop between product design, production, delivery, use, and real-world performance. The objective of this article is to propose an integrated cyber-physical system architecture that links pharmaceutical manufacturing, quality control, distribution, and patient use into a coherent technical framework. The proposed architecture treats the pharmaceutical product not only as a manufactured physical object but also as a data-linked therapeutic system. In this view, quality, traceability, and patient performance are co-produced through connected material, digital, and process flows. The article develops a systems-architecture perspective rather than an empirical study. It synthesises peer-reviewed literature on Pharma 4.0, continuous manufacturing, process analytical technology, digital twins, real-time release, blockchain traceability, cold-chain monitoring, smart packaging, connected drug delivery devices, and digital adherence monitoring. These domains are integrated into a four-layer architecture that connects factory operations to patient-facing use environments. The proposed framework defines four architectural layers: manufacturing, quality control, distribution, and patient use. It then specifies the data, material, and process flows required to connect these layers into a continuous cyber-physical loop. Five tables are used to clarify the architecture problem, the manufacturing layer, the patient-use layer, the end-to-end flows, and the proposed integrated architecture. A pharmaceutical cyber-physical system spanning from raw material to patient outcome represents a potential next frontier in drug product quality, supply chain resilience, and personalised therapy. Such a system would require coordinated action across manufacturers, technology providers, healthcare systems, regulators, and patients. Its value lies not only in automation, but in the creation of a connected pharmaceutical enterprise capable of learning from every stage of the product lifecycle.

Pharmaceutical manufacturing is moving from automated equipment and digitally assisted control toward more autonomous systems capable of interpreting process data, adjusting operating conditions, and supporting quality decisions. This trajectory promises faster response, improved consistency, and more adaptive control across complex production environments. Yet autonomy also changes the nature of manufacturing responsibility because technical decisions increasingly occur inside algorithmic systems rather than through visible human judgement alone. The central problem addressed in this article is the trust deficit created by autonomous pharmaceutical manufacturing. When an algorithm modifies a critical process parameter, detects an anomaly, recommends batch continuation, or contributes to a quality disposition, regulators, operators, quality units, and patients require confidence that the decision remains safe, explainable, reversible, and accountable. Trust cannot be assumed simply because the system performs well during validation; it must be sustained over time as processes, materials, sensors, models, and organisational practices evolve. This article develops an original theory-driven framework for trustworthy autonomous pharmaceutical manufacturing. The framework is structured around three interdependent pillars: human oversight, model drift management, and quality accountability. These pillars are treated not as separate compliance add-ons but as mutually reinforcing design requirements for autonomous manufacturing systems operating in Good Manufacturing Practice environments. The article draws on a theoretical synthesis of peer-reviewed literature on pharmaceutical manufacturing automation, process analytical technology, machine learning, trust in automation, human–autonomy teaming, resilience engineering, socio-technical systems, and model drift. It reframes autonomous manufacturing as a socio-technical trust problem rather than a purely technical optimisation problem. Four tables map the theoretical foundations, oversight architectures, drift-management logic, and integrated Trustworthy System Framework. The proposed framework argues that trustworthiness in autonomous pharmaceutical manufacturing is not a property of an algorithm alone. It emerges from the designed relationship among people, models, process controls, quality systems, audit trails, and governance responsibilities. Autonomous manufacturing will become viable only when the system can remain technically reliable, humanly overseen, and institutionally accountable throughout its lifecycle.